Best Practice & Research Clinical Anaesthesiology
Volume 24, Issue 1 , Pages 95-106 , March 2010

Activated recombinant factor VII (rFVIIa)

  • Oliver Grottke, MD, MPH (Anaesthesiologist)

      Affiliations

    • Department of Anaesthesiology, Institute for Laboratory Animal Science, RWTH Aachen University Hospital, Pauwelsstrasse 30; D-52074 Aachen, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 241 8080972.
    • ,
  • Dietrich Henzler, MD, PhD FRCPC (Professor of Anaesthesia)

      Affiliations

    • Medicine and Physiology, Dalhousie University Halifax, Queen Elisabeth II Health Sciences Center, Department of Anesthesia and Division of Critical Care, 10 West Victoria, 1276 South Park St., Halifax, NS, B3H 2Y9, Canada
    • ,
  • Rolf Rossaint, MD, PhD (Professor and Chairman)

      Affiliations

    • Department of Anaesthesiology, RWTH Aachen University Hospital, Pauwelsstrasse 30; D-52074 Aachen, Germany

References 

  1. Hoffmann Met Monroe D. A cell-based model of hemostasis. Thrombosis and Haemostasis. 2001;85:958–965
  2. Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. Journal of Biotechnology. 2006;124:747–757
  3. Hoffman M, Monroe DM. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Seminars in Hematology. 2001;38:6–9
  4. Monroe DM, Hoffman M, Oliver JA, et al. Platelet activity of high-dose factor VIIa is independent of tissue factor. British Journal of Haematology. 1997;99:542–547
  5. Lisman T, Adelmeijer J, Cauwenberghs S, et al. Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. Journal of Thrombosis and Haemostasis. 2005;3:742–745
  6. Wolberg AS, Allen GA, Monroe DM, et al. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. British Journal of Haematology. 2005;131:645–655
  7. Hedner U, Ezban M. Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis. Annual Review of Medicine. 2008;59:29–41
  8. Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. The Journal of Clinical Investigation. 1983;71:1836–1841
  9. Hedner U, Glazer S, Pingel K, et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet. 1988;2:1193
  10. Hedner U. Treatment of patients with factor VII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thrombosis and Haemostasis. 1999;82:531–539
  11. Parr MJ, Bouillon B, Brohi K, et al. Traumatic coagulopathy: where are the good experimental models?. The Journal of Trauma. 2008;65:766–771
  12. Friederich PW, Henny CP, Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet. 2003;361:201–205
  13. Raobaikady R, Redman J, Ball JA, et al. Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. British Journal Of Anaesthesia. 2005;94:586–591
  14. Von Heymann C, Jonas S, Spies C, et al. Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published data. Critical Care. 2008;12:R14
  15. Ranucci M, Isgrò G, Soro G, et al. Efficacy and safety of recombinant activated factor vii in major surgical procedures: systematic review and meta-analysis of randomized clinical trials. Archives of Surgery. 2008;143:296–304
  16. da Silva Viana J. Recombinant factor VIIa in major abdominal surgery and liver transplantation. Transplantation Proceedings. 2006;38:818–819
  17. Hendriks HG, Meijer K, de Wolf JT, et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation. 2001;71:402–405
  18. Niemann CU, Behrends M, Quan D, et al. Recombinant factor VIIa reduces transfusion requirements in liver transplant patients with high MELD scores. Transfusion Medicine. 2006;16:93–100
  19. Planinsic RM, van der Meer J, Testa G, et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transplantation. 2005;11:895–900
  20. Lodge JP, Jonas S, Jones RM, et al. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transplantation. 2005;11:973–979
  21. Gala B, Quintela J, Aguirrezabalaga J, et al. Benefits of recombinant activated factor VII in complicated liver transplantation. Transplantation Proceedings. 2005;37:3919–3921
  22. Lodge JP, Jonas S, Oussoultzoglou E, et al. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology. 2005;102:269–275
  23. Shao YF, Yang JM, Chau GY, et al. Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. American Journal of Surgery. 2006;191:245–249
  24. Warren O, Mandal K, Hadjianastassiou V, et al. Recombinant activated factor VII in cardiac surgery: a systematic review. The Annals of Thoracic Surgery. 2007;83:707–714
  25. Tanos Met Dunning J. Is recombinant activated factor VII useful for intractable bleeding after cardiac surgery?. Interactive Cardiovascular and Thoracic Surgery. 2006;5:493–498
  26. McCall P, Story DA, Karapillai D. Audit of factor VIIa for bleeding resistant to conventional therapy following complex cardiac surgery. Canadian Journal of Anaesthesia. 2006;53:926–933
  27. Walsham J, Fraser JF, Mullany D, et al. The use of recombinant activated factor VII for refractory bleeding post complex cardiothoracic surgery. Anaesthesia and Intensive Care. 2006;34:13–20
  28. Romagnoli S, Bevilacqua S, Gelsomino S, et al. Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery. Anesthesia and Analgesia. 2006;102:1320–1326
  29. Gelsomino S, Lorusso R, Romagnoli S, et al. Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven): a propensity score analysis. European Journal of Cardio-Thoracic Surgery. 2008;33:64–71
  30. Tritapepe L, De Santis V, Vitale D, et al. Recombinant activated factor VII for refractory bleeding after acute aortic dissection surgery: a propensity score analysis. Critical Care Medicine. 2007;35:1685–1690
  31. Hardy JF, Bélisle S, Van der Linden P. Efficacy and safety of activated recombinant factor VII in cardiac surgical patients. Current Opinion in Anaesthesiology. 2009;22:95–99
  32. Diprose P, Herbertson MJ, O'Shaughnessy D, et al. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex noncoronary cardiac surgery: randomized double-blind placebocontrolled pilot study. British Journal of Anaesthesia. 2005;95:596–602
  33. Ekert H, Brizard C, Eyers R, et al. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy. Blood Coagulation & Fibrinolysis. 2006;17:389–395
  34. Available at: http://clinicaltrials.gov/ct2/show/NCT00154427[accessed June 2009]
  35. Sauaia A, Moore FA, Moore EE, et al. Epidemiology of trauma deaths: a reassessment. Journal of Trauma. 1995;38:185–193
  36. Kauvar DS, Wade CE. The epidemiology and modern management of traumatic hemorrhage: US and international perspectives. Critical Care. 2005;9:1–9
  37. Kenet G, Walden R, Eldad A, et al. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999;354:1879
  38. Rizoli SB, Nascimento B, Osman F, et al. Recombinant activated coagulation factor VII and bleeding trauma patients. Journal of Trauma. 2006;61:1419–1425
  39. Dutton RP, McCunn M, Hyder M, et al. Factor VIIa for correction of traumatic coagulopathy. Journal of Trauma. 2004;57:709–718
  40. Harrison TD, Laskosky J, Jazaeri O, et al. "Low-dose" recombinant activated factor VII results in less blood and blood product use in traumatic hemorrhage. Journal of Trauma. 2005;59:150–154
  41. Geeraedts LM, Kamphuisen PW, Kaasjager HA, et al. The role of recombinant factor VIIa in the treatment of life-threatening haemorrhage in blunt trauma. Injury. 2005;36:495–500
  42. Gowers CJ, Parr MJ. Recombinant activated factor VIIa use in massive transfusion and coagulopathy unresponsive to conventional therapy. Anaesthesia and Intensive Care. 2005;33:196–200
  43. Udy A, Vaghela M, Lawton G, et al. The use of recombinant activated factor VII in the control of haemorrhage following blunt pelvic trauma. Anaesthesia. 2005;60:613–616
  44. Martinowitz Uet Michaelson M. The Israeli Multidisciplinary rFVIIa Task Force Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. Journal of Thrombosis and Haemostasis. 2005;3:640–648
  45. Spinella PC, Perkins JG, McLaughlin DF, et al. The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion. Journal of Trauma. 2008;64:286–293
  46. Boffard KD, Riou B, Warren B, et al. NovoSeven Trauma Study Group. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. Journal of Trauma. 2005;5:8–15
  47. Kluger Y, Riou B, Rossaint R, et al. Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial. Critical Care. 2007;11:R85
  48. Available at: http://clinicaltrials.gov/ct2/show/NCT00184548[accessed June 2009]
  49. Vincent JL, Rossaint R, Riou B, et al. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding–a European perspective. Critical Care. 2006;10:R120
  50. Ronsmans C, Graham WJ. Lancet maternal survival series steering group. Maternal mortality: who, when, where, and why. Lancet. 2006;368:1189–1200
  51. Henrich W, Surbek D, Kainer F, et al. Diagnosis and treatment of peripartum bleeding. Journal Of Perinatal Medicine. 2008;36:467–478
  52. Ahonen J, Jokela R, Korttila K. An open non-randomized study of recombinant activated factor VII in major postpartum haemorrhage. Acta Anaesthesiologica Scandinavica. 2007;51:929–936
  53. Franchini M, Franchi M, Bergamini V, et al. A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage. Seminars in Thrombosis and Hemostasis. 2008;34:104–112
  54. Sachs B, Delacy D, Green J, et al. Recombinant activated factor VII in spinal surgery: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial. Spine. 2007;32:2285–2293
  55. Johansson PI, Eriksen K, Nielsen SL, et al. Recombinant FVIIa decreases perioperative blood transfusion requirement in burn patients undergoing excision and skin grafting–results of a single centre pilot study. Burns. 2007;33:435–440
  56. Kucher N, Castellanos LR, Quiroz R, et al. Time trends in warfarin-associated hemorrhage. American Journal of Cardiology. 2004;94:403–406
  57. Levy JH, Tanaka KA, Dietrich W. Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology. 2008;109:918–926
  58. Leissinger CA, Blatt PM, Hoots WK, et al. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. American Journal of Hematology. 2008;83:137–143
  59. Mallarkey G, Brighton T, Thomson A, et al. An evaluation of eptacog alfa in nonhaemophiliac conditions. Drugs. 2008;68:1665–1689
  60. Girard P, Nony P, Erhardtsen E, et al. Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol. Thrombosis and Haemostasis. 1998;80:109–113
  61. Dager WE, King JH, Regalia RC, et al. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy. 2006;26:1091–1098
  62. Levi M. Emergency reversal of antithrombotic treatment. Internal and Emergency Medicine. 2009;4:137–145
  63. Levi M, Bijsterveld NR, Keller TT. Recombinant factor VIIa as an antidote for anticoagulant treatment. Seminars in Hematology. 2004;41:65–69
  64. Baglin TP, Keeling DM, Watson HG. British committee for standards in haematology. Guidelines on oral anticoagulation (warfarin). –2005 update British Journal of Haematology. 2006;132:277–285
  65. Santagostino E, Mancuso ME, Rocino A, et al. A prospective randomized trial of high and standard dosages of re-combinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. Journal of Thrombosis and Haemostasis. 2006;4:367–371
  66. Konkle B, Friedrich U, Abrams Z. Secondary prophylactic treatment with rFVIIA in patients with haemophilia A or B and inhibitors with high requirements for on-demand treatment. Haemophilia. 2006;12:363
  67. Heuer L, Blumenberg D. Management of bleeding in a multi-transfused patient with positive HLA Class I alloantibodies and thrombocytopenia associated with platelets dysfunction refractory to transfusion of cross matched platelets. Blood Coagulation Fibrinolysis. 2005;16:287–290
  68. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clinical Pharmacology and Therapeutics. 1994;55:638–648
  69. Hedner U. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies. Thrombosis and Haemostasis. 2008;100:557–562
  70. Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Seminars in Thrombosis and Hemostasis. 2000;26:385–391
  71. Hedner U, Erhardtsen E. Potential role of recombinant factor VIIa as a hemostatic agent. Clinical Advances in Hematology & Oncology. 2003;1:112–119
  72. Stanworth SJ, Birchall J, Doree CJ, et al. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database of Systermic Reviews. 2007;2:CD005011
  73. Hsia CC, Chin-Yee IH, McAlister VC. Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. Annals of Surgery. 2008;248:61–68
  74. Meng ZH, Wolberg AS, Monroe DM, et al. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. Journal of Trauma. 2003;55:886–891
  75. Negrier C, Dargaud Y, Bordet JC. Basic aspects of bypassing agents. Haemophilia. 2006;12:48–52
  76. Spahn DR, Rossaint R. Coagulopathy and blood component transfusion in trauma. British Journal of Anaesthesia. 2005;95:130–139
  77. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood. 2004;104:3858–3864
  78. Eikelboom JW, Bird R, Blythe D, et al. Recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coagulation & Fibrinolysis. 2003;14:713–717
  79. Moisescu E, Ardelean L, Simion I, et al. Recombinant factor VIIa treatment of bleeding associated with acute renal failure. Blood Coagulation & Fibrinolysis. 2000;11:575–577
  80. Carr ME, Martin E. Recombinant factor VIIa: clinical applications for an intravenous hemostatic agent with broad-spectrum potential. Expert Review of Cardiovascular Theraphy. 2004;2:661–674
  81. Telgt DS, Macik BG, McCord DM, et al. Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor. Thrombosis Research. 1989;56:603–609
  82. Rao LV, Rapaport SI. Factor VIIa-catalyzed activation of factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused factor VIIa. Blood. 1990;75:1069–1073
  83. Shima M. Understanding the hemostatic effects of recombinant factor VIIa by clot wave form analysis. Seminars in Hematology. 2004;41:125–131
  84. Sørensen B, Johansen P, Christiansen K, et al. Whole blood coagulation thromboelastographic profiles employing minimal tissue factor activation. Journal of Thrombosis and Haemostasis. 2003;1:551–558
  85. Dehmel H, Werwitzke S, Trummer A, et al. Thrombelastographic monitoring of recombinant factor VIIa in acquired haemophilia. Haemophilia. 2008;14:736–742
  86. Young G, Ebbesen LS, Viuff D, et al. Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagulation & Fibrinolysis. 2008;19:276–282
  87. Gabriel DA, Carr M, Roberts HR. Monitoring coagulation and the clinical effects of recombinant factor VIIa. Seminars in Hematology. 2004;41:20–24
  88. Dargaud Y, Lambert T, Trossaert M. New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors. Haemophilia. 2008;14:20–27
  89. Young G, Yonekawa KE, Nakagawa PA, et al. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. Blood Coagulation & Fibrinolysis. 2007;18:547–553
  90. James KM, Melikian CN, Chowdary P, et al. Thromboelastography-guided recombinant factor VIIa administration in a patient with refractory autoimmune idiopathic thrombocytopenia. Anesthesia and Analgesia. 2008;107:402–405
  91. Bartal C, Yitzhak A. The role of thromboelastometry and recombinant factor VIIa in trauma. Current Opinion in Anaesthesiology. 2009;22:281–288
  92. Levrat A, Gros A, Rugeri L, et al. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients. British Journal of Anaesthesia. 2008;100:792–797
  93. Cid AR, Lorenzo JI, Haya S, et al. A comparison of FVII: C and FVIIa assays for the monitoring of recombinant factor VIIa treatment. Haemophilia. 2001;7:39–41
  94. Hemker HC, Giesen P, AlDieri R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiology of Haemostasis and Thrombosis. 2002;32:249–253
  95. Pusateri AE, Park MS. Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma. Critical Care. 2005;9:15–24
  96. Levi M, Peters M, Büller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Critical Care Medicine. 2005;33:883–890
  97. Bui JD, Despotis GD, Trulock EP, et al. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. The Journal of Thoracic and Cardiovascular Surgery. 2002;124:852–854
  98. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation. 2002;106:2550–2554
  99. Bijsterveld NR, Vink R, van Aken BE, et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. British Journal of Haematology. 2004;124:653–658
  100. Fridberg MJ, Hedner U, Roberts HR, et al. A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects. Blood Coagulation & Fibrinolysis. 2005;16:259–266
  101. Wolzt M, Levi M, Sarich TC, et al. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thrombosis and Haemostasis. 2004;91:1090–1096
  102. Roberts HR. Clinical experience with activated factor VII: focus on safety aspects. Blood Coagulation & Fibrinolysis. 1998;9:115–118
  103. Roberts HR. Recombinant factor VIIa (Novoseven) and the safety of treatment. Seminars in Hematology. 2001;38:48–50
  104. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. The Journal of the American Medical Association. 2006;295:293–298
  105. Available at: www.emea.europa.eu//humandocs/PDFs/EPAR/Novoseven/072995en8b[accessed June 2009]
  106. Kozek-Langenecker S. Management of massive operative blood loss. Minerva Anestesiologica. 2007;73:401–415
  107. Grottke O, Henzler D, Rossaint R. Use of blood and blood products in trauma. Best Practice & Research. Clinical Anaesthesiology. 2007;21:257–270
  108. Brohi K, Cohen MJ, Davenport RA. Acute coagulopathy of trauma: mechanism, identification and effect. Current Opinion in Critical Care. 2007;13:680–685
  109. Spahn DR, Cerny V, Coats TJ, et al. Task Force for Advanced Bleeding Care in Trauma. Management of bleeding following major trauma: a European guideline. Critical Care. 2007;11:R17

PII: S1521-6896(09)00069-X

doi: 10.1016/j.bpa.2009.09.005

Best Practice & Research Clinical Anaesthesiology
Volume 24, Issue 1 , Pages 95-106 , March 2010

Article Tools